** Shares of drugmaker Alkermes ALKS.O rise 6.38% to $34
** Co posts Q4 sales of $430 million, beating analysts' estimate of $379 million - LSEG
** Sees 2025 revenue between $1.3 billion and $1.4 billion vs est $1.4 billion
** Expects mid-stage study data of neurological disorder drug in H2 2025
** Plans to begin early-stage study of drugs to treat sleep disorders
** In the last 12 months, ALKS rose 7.6%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。